---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-006473"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:22:32.058274+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Tonix doses first patient in Phase 2 OASIS trial of TNX-102 SL for acute stress reaction

## Summary
- Phase 2 OASIS trial evaluating TNX-102 SL in reducing severity of acute stress reaction and frequency of acute stress disorder.
- Trial sponsored by UNC Institute for Trauma Recovery with a $3 million grant from the U.S. Department of Defense.
- Plans to enroll ~180 motor vehicle collision survivors at U.S. emergency departments; randomized to TNX-102 SL 5.6 mg or placebo for two weeks.
- Topline results expected in the second half of 2026.

## SEC filing metadata
- accession: 0001999371-25-006473
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/0001999371-25-006473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125006473/tnxp-8k_052125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-006473
- JSON: https://secwatch.observer/filing/0001999371-25-006473.json
- Plain text: https://secwatch.observer/filing/0001999371-25-006473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.